

James G Kublin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7793332/publications.pdf>

Version: 2024-02-01

57
papers

3,977
citations

236833

25
h-index

143943

57
g-index

60
all docs

60
docs citations

60
times ranked

4842
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2022, 375, 43-50.	6.0	788
2	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac124.	0.4	25
3	Analysis of the HIV Vaccine Trials Network 702 Phase 2bâ€“3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. <i>Journal of Infectious Diseases</i> , 2022, 226, 246-257.	1.9	11
4	Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120â€“MF59 in Adults. <i>New England Journal of Medicine</i> , 2021, 384, 1089-1100.	13.9	144
5	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. <i>New England Journal of Medicine</i> , 2021, 384, 1003-1014.	13.9	270
6	Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. <i>PLoS Pathogens</i> , 2021, 17, e1009363.	2.1	19
7	PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection. <i>PLoS Pathogens</i> , 2021, 17, e1009594.	2.1	34
8	Reference and point-of-care testing for G6PD deficiency: Blood disorder interference, contrived specimens, and fingerstick equivalence and precision. <i>PLoS ONE</i> , 2021, 16, e0257560.	1.1	12
9	Increasing Black, Indigenous and People of Color participation in clinical trials through community engagement and recruitment goal establishment. <i>PLoS ONE</i> , 2021, 16, e0258858.	1.1	62
10	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2021, , eab3435.	6.0	145
11	Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003868.	3.9	20
12	Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults. <i>Clinical Infectious Diseases</i> , 2020, 71, 1481-1490.	2.9	9
13	Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. <i>Clinical Infectious Diseases</i> , 2020, 72, 50-60.	2.9	15
14	Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. <i>Lancet HIV</i> , 2020, 7, e688-e698.	2.1	58
15	A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa. <i>EClinicalMedicine</i> , 2020, 21, 100313.	3.2	52
16	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <i>PLoS Medicine</i> , 2020, 17, e1003038.	3.9	27
17	A mixed methods investigation of implementation barriers and facilitators to a daily mobile phone sexual risk assessment for young women in Soweto, South Africa. <i>PLoS ONE</i> , 2020, 15, e0231086.	1.1	8
18	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. <i>PLoS Medicine</i> , 2020, 17, e1003117.	3.9	8

#	ARTICLE	IF	CITATIONS
19	Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA. <i>Journal of the International AIDS Society</i> , 2019, 22, e25373.	1.2	6
20	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	46
21	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2019, 6, e737-e749.	2.1	43
22	Antigenic competition in CD4 ⁺ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	18
23	Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination. <i>PLoS ONE</i> , 2019, 14, e0225622.	1.1	20
24	Daily Vaginal Swabs and Mobile Phone Sex Report for Assessing HIV Virion Exposure Prospectively Among a Cohort of Young Sexually Active Women in South Africa (HVTN 915). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, e39-e48.	0.9	5
25	Vaginal practices among women at risk for HIV acquisition in Soweto, South Africa. <i>Southern African Journal of HIV Medicine</i> , 2019, 20, 866.	0.3	2
26	Beyond Blood Smears: Qualification of Plasmodium 18S rRNA as a Biomarker for Controlled Human Malaria Infections. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 1466-1476.	0.6	41
27	Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study. <i>Scientific Reports</i> , 2018, 8, 6066.	1.6	17
28	Mobile Phone Questionnaires for Sexual Risk Data Collection Among Young Women in Soweto, South Africa. <i>AIDS and Behavior</i> , 2018, 22, 2312-2321.	1.4	16
29	Utilizing gnotobiotic models to inform the role of the microbiome in vaccine response heterogeneity. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 1-8.	1.5	8
30	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. <i>Lancet HIV</i> , 2018, 5, e366-e378.	2.1	86
31	Complete attenuation of genetically engineered <i>Plasmodium falciparum</i> sporozoites in human subjects. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	91
32	The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States. <i>Vaccines</i> , 2017, 5, 13.	2.1	11
33	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. <i>Statistical Communications in Infectious Diseases</i> , 2017, 9, .	0.2	62
34	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. <i>PLoS ONE</i> , 2017, 12, e0185959.	1.1	27
35	Lower Viral Loads and Slower CD4 ⁺ T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02. <i>Journal of Infectious Diseases</i> , 2016, 214, 379-389.	1.9	6
36	Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. <i>Current Opinion in Virology</i> , 2016, 17, 57-65.	2.6	14

#	ARTICLE	IF	CITATIONS
37	Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. <i>PLoS ONE</i> , 2016, 11, e0161753.	1.1	16
38	Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. <i>PLoS Pathogens</i> , 2016, 12, e1005742.	2.1	81
39	A New Model for Catalyzing Translational Science: The Early Stage Investigator Mentored Research Scholar Program in HIV Vaccines. <i>Clinical and Translational Science</i> , 2015, 8, 166-168.	1.5	4
40	Enhancing Diversity in the Public Health Research Workforce: The Research and Mentorship Program for Future HIV Vaccine Scientists. <i>American Journal of Public Health</i> , 2015, 105, 823-830.	1.5	28
41	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. <i>PLoS ONE</i> , 2015, 10, e0136626.	1.1	23
42	Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models. <i>EBioMedicine</i> , 2015, 2, 2062-2069.	2.7	14
43	Use of placebos in Phase 1 preventive HIV vaccine clinical trials. <i>Vaccine</i> , 2015, 33, 749-752.	1.7	2
44	Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials. <i>Vaccine</i> , 2015, 33, 2347-2353.	1.7	34
45	Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. <i>PLoS ONE</i> , 2015, 10, e0137666.	1.1	30
46	Safety and Comparability of Controlled Human <i>Plasmodium falciparum</i> Infection by Mosquito Bite in Malaria-Naïve Subjects at a New Facility for Sporozoite Challenge. <i>PLoS ONE</i> , 2014, 9, e109654.	1.1	21
47	Tuberculosis Vaccines and Prevention of Infection. <i>Microbiology and Molecular Biology Reviews</i> , 2014, 78, 650-671.	2.9	133
48	Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 388-396.	4.6	108
49	Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses. <i>PLoS ONE</i> , 2014, 9, e103446.	1.1	9
50	Lessons Learned from HIV Vaccine Clinical Efficacy Trials. <i>Current HIV Research</i> , 2014, 11, 441-449.	0.2	38
51	Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. <i>New England Journal of Medicine</i> , 2013, 369, 2083-2092.	13.9	518
52	In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Nonvaccine Prevention Modalities. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1513-1523.	0.5	19
53	HIV Vaccine Trials Network: activities and achievements of the first decade and beyond. <i>Clinical Investigation</i> , 2012, 2, 245-254.	0.0	16
54	Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. <i>Journal of Clinical Investigation</i> , 2012, 122, 359-367.	3.9	127

#	ARTICLE	IF	CITATIONS
55	Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. <i>Lancet Infectious Diseases</i> , 2011, 11, 507-515.	4.6	330
56	HIV-1 Vaccines and Adaptive Trial Designs. <i>Science Translational Medicine</i> , 2011, 3, 79ps13.	5.8	60
57	A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens. <i>Statistical Communications in Infectious Diseases</i> , 2011, 3, .	0.2	23